Abstract: The present application discloses a reconfigurable transmitter and receiver, and methods for reconfiguring the same. A system adaptive control circuit generates a control signal according to frequency band information of an input signal; a system clock circuit generates a system clock; a preprocessing circuit preprocesses a received baseband signal according to the system clock and the control signal, to generate a frequency band signal; a digital intermediate frequency processing circuit processes the frequency band signal according to the system clock and the control signal, to generate a digital intermediate frequency signal; a digital-to-analog conversion circuit processes the digital intermediate frequency signal according to the system clock and the control signal, to generate an analog signal; and an analog transmitting circuit transmits the analog signal.

Abstract: A predistortion processing apparatus: an auxiliary feedback module, configured to: extract a nonlinear distortion signal from an analog signal, and input an obtained feedback signal corresponding to the nonlinear distortion signal into an auxiliary model coefficient training module; the auxiliary model coefficient training module, configured to: train an auxiliary coefficient according to the feedback signal and a predistortion signal, and transmit a first auxiliary coefficient obtained through training to a predistortion processing module; a radio frequency signal feedback module, configured to extract a fundamental wave feedback signal; a predistortion model coefficient training module, configured to: train a predistortion coefficient according to the predistortion signal and the fundamental wave feedback signal, and transmit an obtained predistortion coefficient to the predistortion processing module; the predistortion processing module, configured to: perform predistortion processing on an input intermedi

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Abstract: Embodiments of the present invention disclose a pre-distortion system, including a pre-distortion circuit, a transmission circuit, a power amplifier, a feedback circuit, and a learning circuit. The pre-distortion circuit acquires an in-band intermodulation distortion model coefficient vector, a cross-band modulation distortion model coefficient vector, and an out-of-band intermodulation distortion model coefficient vector that are learned by the learning circuit according to an output signal of the power amplifier, and performs pre-distortion processing on an input digital intermediate frequency signal. Correspondingly, the embodiments of the present invention further disclose a pre-distortion method, which can eliminate impact caused by out-of-band intermodulation distortion on the power amplifier.

Abstract: A predistortion processing apparatus: an auxiliary feedback module, configured to: extract a nonlinear distortion signal from an analog signal, and input an obtained feedback signal corresponding to the nonlinear distortion signal into an auxiliary model coefficient training module; the auxiliary model coefficient training module, configured to: train an auxiliary coefficient according to the feedback signal and a predistortion signal, and transmit a first auxiliary coefficient obtained through training to a predistortion processing module; a radio frequency signal feedback module, configured to extract a fundamental wave feedback signal; a predistortion model coefficient training module, configured to: train a predistortion coefficient according to the predistortion signal and the fundamental wave feedback signal, and transmit an obtained predistortion coefficient to the predistortion processing module; the predistortion processing module, configured to: perform predistortion processing on an input intermedi

Abstract: Compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Abstract: The present application discloses a reconfigurable transmitter and receiver, and methods for reconfiguring the same. A system adaptive control circuit generates a control signal according to frequency band information of an input signal; a system clock circuit generates a system clock; a preprocessing circuit preprocesses a received baseband signal according to the system clock and the control signal, to generate a frequency band signal; a digital intermediate frequency processing circuit processes the frequency band signal according to the system clock and the control signal, to generate a digital intermediate frequency signal; a digital-to-analog conversion circuit processes the digital intermediate frequency signal according to the system clock and the control signal, to generate an analog signal; and an analog transmitting circuit transmits the analog signal.

Abstract: Embodiments of the present invention disclose a pre-distortion system, including a pre-distortion circuit, a transmission circuit, a power amplifier, a feedback circuit, and a learning circuit. The pre-distortion circuit acquires an in-band intermodulation distortion model coefficient vector, a cross-band modulation distortion model coefficient vector, and an out-of-band intermodulation distortion model coefficient vector that are learned by the learning circuit according to an output signal of the power amplifier, and performs pre-distortion processing on an input digital intermediate frequency signal. Correspondingly, the embodiments of the present invention further disclose a pre-distortion method, which can eliminate impact caused by out-of-band intermodulation distortion on the power amplifier.

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Abstract: Compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.

Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan amorphous potassium salt.

Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.

Abstract: The present invention provides pro-drugs of D-gamma-glutamyl-[D/L]-tryptophan, said pro-drugs are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein G is C1-C8 alkyl or benzyl, T is C1-C8 alkyl or benzyl, and * is a chiral carbon in a (R) or (S) configuration, provided that when * is in the (R) configuration, at least one of G and T is C5-C8 alkyl; and use of compounds of Formula I in a pharmaceutical composition.

Abstract: Provided are carboxylic ester derivatives of formula (I), methods of preparing them, and methods for using them. These compounds are prodrugs of D-isoglutamyl-[D/L]-tryptophan. The in vitro bioconversion of some of the prodrugs to the parent drug D-isoglutamyl-D-tryptophan (or thymodepressin) was tested in human hepatocytes and in human blood. In vivo pharmacokinetic studies following oral administration of some of the prodrugs to rats are also reported.

Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D-tryptophan organic ammonium salts (1:1).

Abstract: The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed.

Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.